

i

UNITED STAT DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR				ATTORNEY DOCKET NO.	
09/509,932		00 AN	TONI-ZIMMER	MANN	D	788-027	
-			HM12/1001	\neg		EXAMINER	
JAMES V COSTIGAN HEDMAN GIBSON & COSTIGAN 1185 AVENUE OF THE AMERICAS					JAGO		
					ART UNIT	PAPER NUMBER	
NEW YORK N	Y 10036-26	O1	.	,	1614	•	
					DATE MAILED:		
						10/01/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

		Amaliantia	an No.	A U A \						
. · · • • • • • • • • • • • • • • • • •		Application		Applicant(s)						
• 18	Office Action Summany	09/509,93		ANTONI-ZIMMERMANN ET AL.						
Office Action Summary		Examiner		Art Unit						
-·	- The MAILING DATE of this communication	Donna A.		1614	dross					
Period fo		n appears on the	cover sneet with the	: correspondence au	uress					
THE N - Exten after 3 - If the - If NO - Failur - Any re	DRTENED STATUTORY PERIOD FOR F MAILING DATE OF THIS COMMUNICATI sions of time may be available under the provisions of 37 C SIX (6) MONTHS from the mailing date of this communicati period for reply specified above is less than thirty (30) days period for reply is specified above, the maximum statutory e to reply within the set or extended period for reply will, by eply received by the Office later than three months after the d patent term adjustment. See 37 CFR 1.704(b).	ION. CFR 1.136(a). In no ever on. s, a reply within the statu period will apply and wing statute, cause the apply	ent, however, may a reply be utory minimum of thirty (30) d Il expire SIX (6) MONTHS fro lication to become ABANDON	timely filed lays will be considered timely om the mailing date of this co NED (35 U.S.C. § 133).	/. ommunication.					
1)[1) Responsive to communication(s) filed on									
2a) <u></u> □	This action is FINAL . 2b)									
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.									
Dispositi	on of Claims									
4)🛛	4) Claim(s) 1-8 is/are pending in the application.									
•	4a) Of the above claim(s) is/are withdrawn from consideration.									
5)	S) Claim(s) is/are allowed.									
6)⊠	6) Claim(s) <u>1-4</u> is/are rejected.									
7)🖂	Claim(s) <u>5-8</u> is/are objected to.									
8)□	Claim(s) are subject to restriction a	and/or election re	equirement.							
Applicati	on Papers									
<i>,</i> —	The specification is objected to by the Exa									
10) 🔲 🗆	The drawing(s) filed on is/are: a)□									
	Applicant may not request that any objection									
11)[7	he proposed drawing correction filed on			roved by the Examine	er.					
If approved, corrected drawings are required in reply to this Office action.										
. —	The oath or declaration is objected to by the	ne Examiner.								
	nder 35 U.S.C. §§ 119 and 120		d251100 0440	(a) (d) au (f)						
·	Acknowledgment is made of a claim for for for for for for for for formed and both the formed are formed as formed a	oreign priority un	der 35 U.S.C. § 119	(a)-(d) or (i).						
a)L		imanta haya haa	n received							
	 Certified copies of the priority docu Certified copies of the priority docu 			ation No						
	2. Copies of the certified copies of the				Stage					
	application from the Internation ee the attached detailed Office action for	al Bureau (PCT	Rule 17.2(a)).		Olage					
14)[] A	cknowledgment is made of a claim for do	mestic priority ur	nder 35 U.S.C. § 119	e) (to a provisional	application).					
	The translation of the foreign language cknowledgment is made of a claim for do									
Attachment		-								
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-94 nation Disclosure Statement(s) (PTO-1449) Paper N			ary (PTO-413) Paper No(al Patent Application (PTO						

Application/Control Number: 09/509,932

Art Unit: 1614

DETAILED ACTION

Claims 1-8 are presented for examination.

The information disclosure statements filed on April 3, 2000 and June 7, 2000 in paper numbers 3 and 6 have been reviewed and considered. See enclosed copy of PTO FORM 1449.

Claim Objections

Claims 5-8 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP § 608.01(n). Accordingly, the claims 5-8 have not been further treated on the merits.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to

Application/Control Number: 09/509,932

Art Unit: 1614

consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Valcke et al U.S. Pat. No. 5,714,507 A.

The claims are drawn to a biocide composition containing 2-methylisothiazolin-3-one and 3-iodo-2-propynyl-N-butylcarbamate in combination and excluding 5-chloro-2-methylisothiazolin-3-one wherein the biocide agents are combined in a weight ration of (100-1):(1-50) or (15-1): (1-8).

Valke et al. teach biocide compositions comprising the active ingredients (I) and (II) (column 1, lines 18-27) and further comprising other microbiocides such as 3-iodo-2-propynyl-N-butylcarbamate (column 11, line 31) and isothiazolinones such as N-methylisothiazolin-3-one (column 11, lines 56-57 and column 12, lines 50-58). It differs from the instant invention in that the weight ratios are not recited in the composition.

Although the weight ratios are not recited, it is prima facie obvious to combine two compositions, each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. *In re Kerkhoven* 205 USPQ 1069. Motivation to combine flows logically from their having been individually taught in the prior art. *In re Crockett* 126 USPQ 186, 188. See also *In re Shannon* 148 USPQ 504 (one step laminate is obvious from two step laminate).



Application/Control Number: 09/509,932

Art Unit: 1614

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Donna A. Jagoe whose telephone number is (703) 306-5826. The examiner can normally be reached on 6:30 A.M. - 3 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3230 for regular communications and (703) 308-7921 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0193.

dj September 26, 2001 FREDSRICK KRASS PRIMARY EXAMINER __ GBQUP_1800